Zacks Research Weighs in on Globus Medical Q3 Earnings

Globus Medical, Inc. (NYSE:GMED) – Research analysts at Zacks Research upped their Q3 2026 EPS estimates for shares of Globus Medical in a note issued to investors on Thursday, August 27th. Zacks Research analyst Team now anticipates that the medical device company will post earnings of $1.18 per share for the quarter, up from their prior forecast of $1.16. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $4.99 per share. Zacks Research also issued estimates for Globus Medical’s FY2026 earnings at $4.97 EPS, Q1 2027 earnings at $1.13 EPS, Q2 2027 earnings at $1.33 EPS, Q3 2027 earnings at $1.24 EPS, FY2027 earnings at $5.06 EPS, Q1 2028 earnings at $1.38 EPS and Q2 2028 earnings at $1.46 EPS.

Several other analysts have also issued reports on GMED. Royal Bank Of Canada reduced their target price on Globus Medical from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Needham & Company LLC boosted their price target on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Wall Street Zen cut shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Wells Fargo & Company reduced their price objective on shares of Globus Medical from $103.00 to $99.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Finally, BMO Capital Markets assumed coverage on shares of Globus Medical in a report on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $101.77.

Globus Medical Trading Down 0.6%

Shares of GMED stock opened at $82.57 on Friday. The stock has a market cap of $11.09 billion, a P/E ratio of 21.12, a price-to-earnings-growth ratio of 1.34 and a beta of 0.95. Globus Medical has a 1 year low of $54.15 and a 1 year high of $101.40. The stock has a 50 day simple moving average of $81.05 and a 200 day simple moving average of $84.63.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.10 by $0.24. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The company had revenue of $789.61 million for the quarter, compared to analysts’ expectations of $782.88 million. During the same period last year, the firm earned $0.86 earnings per share. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS.

Insiders Place Their Bets

In other news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. The trade was a 4.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stephen T. Zarrilli sold 25,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the sale, the director owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 18.38% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Globus Medical by 71,618.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 716,469 shares of the medical device company’s stock valued at $62,555,000 after purchasing an additional 715,470 shares in the last quarter. WCM Investment Management LLC bought a new stake in shares of Globus Medical during the 1st quarter valued at approximately $16,965,000. SG Americas Securities LLC grew its holdings in shares of Globus Medical by 241.1% during the 1st quarter. SG Americas Securities LLC now owns 340,452 shares of the medical device company’s stock valued at $29,333,000 after purchasing an additional 240,642 shares during the last quarter. Artemis Investment Management LLP increased its position in Globus Medical by 43.7% during the 4th quarter. Artemis Investment Management LLP now owns 738,595 shares of the medical device company’s stock worth $64,487,000 after purchasing an additional 224,587 shares in the last quarter. Finally, Hyperion Capital Advisors LP acquired a new position in Globus Medical during the 4th quarter worth approximately $12,822,000. Institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.